Evidence map›Paper›PMID 35368130›Full record

ArticleInternational journal of urology : official journal of the Japanese Urological Association2022

Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.

Reza Sari Motlagh, Victor M Schuettfort, Keiichiro Mori, Satoshi Katayama, Pawel Rajwa, Abdulmajeed Aydh, Nico C Grossmann, Ekaterina Laukhtina, Benjamin Pradere, Hadi Mostafai and 9 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of urology : official journal of the Japanese Urological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 17 institutions in 13 countries.

Reza Sari Motlagh *Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-3819-9911
Victor M Schuettfort *Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Keiichiro MoriDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-6147-6569
Satoshi KatayamaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Pawel RajwaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Abdulmajeed AydhDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-6078-6816
Nico C GrossmannDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-8698-6461
Ekaterina LaukhtinaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-8953-0272
Benjamin PradereDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Hadi MostafaiDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Fahad QuhalDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Mohammad AbufarajDepartment of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Richard LeeDepartment of Urology, Weill Cornell Medical College, New York, New York, USA.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada.
Yair LotanDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Eva ComprateDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Marco MoschiniUnit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0002-3084-2458
Paolo GonteroDivision of Urology, Molinette Hospital, University of Torino School of Medicine, Torino, Italy.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Comprehensive Cancer Center Vienna · ATAl-Ahliyya Amman University · JOCornell University · USFondazione Ricerca Molinette · ITIRCCS Ospedale San Raffaele · ITJikei University School of Medicine · JPKing Fahad Specialist Hospital · SAKing Fahd Medical City · SAMedical University of Silesia · PLMedical University of Vienna · ATOkayama University · JPSechenov University · RUTabriz University of Medical Sciences · IRThe University of Texas Southwestern Medical Center · USUniversität Hamburg · DEUniversité de Montréal · CAUniversity of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesInsulin-like growth factor-I and its binding proteins are involved in cancer development, progression, and metastasis. In urothelial carcinoma, the impact of this pathway is still poorly investigated. The present large cohort study aimed to evaluate the association of preoperative circulating levels of insulin-like growth factor-I, insulin-like growth factor-I binding protein-2 and -3 on outcomes after radical cystectomy.

methodsA retrospective cohort study of the plasma specimens from 1036 consecutive urothelial carcinoma patients who were treated with radical cystectomy. The primary and secondary outcomes were adverse histopathological features and survival outcomes. Binominal logistic regression and multivariable Cox regression analyses were performed to assess the association of plasma levels of insulin-like growth factor-I, insulin-like growth factor-I binding protein-2 and -3 with outcomes.

resultsOn multivariable analysis adjusting for the effects of preoperative variables, lower insulin-like growth factor-I binding protein-2 levels were associated with an increased risk of lymph node metastasis and (any non-organ confined disease) any non-organ confined disease. Insulin-like growth factor-I binding protein-3 levels were also inversely independently associated with lymph node metastasis. Receiver operating characteristic curve analysis showed that the addition of insulin-like growth factor-I binding proteins biomarkers to a reference model significantly improved the discriminating ability for the prediction of lymph node metastasis (+10.0%, P < 0.001). On multivariable Cox regression models, lower levels of both insulin-like growth factor-I binding protein-2 and -3 plasma levels were associated with recurrence-free survival, cancer-specific survival, and overall survival. insulin-like growth factor-I binding protein-2 and -3 levels and improved the discrimination of a standard reference model for the prediction of recurrence-free survival, cancer-specific survival, and overall survival (+4.9%, 4.9%, 2.3%, respectively).

conclusionsPreoperative insulin-like growth factor-I binding protein-2 and -3 are significantly associated with features of biologically and clinically aggressive urothelial carcinoma. These biomarkers improved prognostic urothelial carcinoma models.

Indexed as

Carcinoma, Transitional CellInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IUrinary Bladder NeoplasmsBiomarkersCarrier ProteinsCohort StudiesCystectomyHumansLymphatic MetastasisNeoplasm StagingPrognosisRetrospective StudiesBiomarkersCarrier ProteinsIGFBP2 protein, humanIGFBP3 protein, humanInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Ibinding proteinsbladder cancerIGF-Iinsulin-like growth factorradical cystectomyurothelial carcinoma

Identifiers

PMID35368130
PMCPMC9543826
OpenAlexW4224093915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.